PT - JOURNAL ARTICLE AU - Lynd, Amy AU - Gonahasa, Samuel AU - Staedke, Sarah G AU - Oruni, Ambrose AU - Maiteki-Sebuguzi, Catherine AU - Hancock, Penny AU - Knight, Erin AU - Dorsey, Grant AU - Opigo, Jimmy AU - Yeka, Adoke AU - Katureebe, Agaba AU - Kyohere, Mary AU - Hemingway, Janet AU - Kamya, Moses R AU - McDermott, Daniel AU - Lucas, Eric R. AU - Donnelly, Martin J TI - LLIN Evaluation in Uganda Project (LLINEUP) – <em>Plasmodium</em> infection prevalence and genotypic markers of insecticide resistance in <em>Anopheles</em> vectors from 48 districts of Uganda AID - 10.1101/2023.07.31.23293323 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.31.23293323 4099 - http://medrxiv.org/content/early/2023/08/05/2023.07.31.23293323.short 4100 - http://medrxiv.org/content/early/2023/08/05/2023.07.31.23293323.full AB - Background In 2017-2019, we conducted a large-scale, cluster-randomised trial (LLINEUP) to evaluate long-lasting insecticidal nets (LLINs) treated with a pyrethroid insecticide plus the synergist piperonyl butoxide (PBO LLINs), as compared to conventional, pyrethroid-only LLINs across 104 health sub-districts (HSDs) in Uganda. In LLINEUP, and similar trials in Tanzania, PBO LLINs were found to provide greater protection against malaria than conventional LLINs, reducing parasitaemia and vector density. In the LLINEUP trial, cross-sectional entomological surveys were carried out at baseline and then every 6 months for two years. In each survey, ten households per HSD were randomly selected for indoor household entomological collections.Results Overall, 5395 female Anopheles mosquitoes were collected from 5046 households. The proportion of mosquitoes infected with Plasmodium falciparum did not change significantly over time, while infection with non-falciparum malaria decreased in An. gambiae s.s, but not An. funestus. The frequency of genetic markers associated with pyrethroid resistance increased significantly over time, but the rate of change was not different between the two LLIN types. The knock-down resistance (kdr) mutation Vgsc-995S declined over time as Vgsc-995F, the alternative resistance mutation at this codon, increased. Vgsc-995F appears to be spreading into Uganda.Conclusions Distribution of LLINs in Uganda was associated with reductions in parasite prevalence and vector density, but the proportion of infective mosquitoes remained stable, suggesting that the potential for transmission persisted. The increased frequency of markers of pyrethroid resistance indicates that LLIN distribution favoured the evolution of resistance within local vectors and highlights the potential benefits of resistance management strategies.Trial registration: This study is registered with ISRCTN, ISRCTN17516395. Registered 14 February 2017, http://www.isrctn.com/ISRCTN17516395Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN17516395Funding StatementThis project was supported by The Against Malaria Foundation. Additional funding was provided by Award Number R01AI116811 from the National Institutes of Allergy and Infectious Diseases (NIAID) and a Wellcome Trust MSc Fellowship in Public Health and Tropical Medicine (Oruni-203511/Z/16/Z). The content of the manuscript is solely the responsibility of the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ugandan National Council for Science and Technology (UNCST Ref HS 2176), Makerere University School of Medicine Research &amp; Ethics Committee (SOMREC 2016-133), London School of Hygiene &amp; Tropical Medicine Ethics Committee (LSHTM Ref 12019), and the Liverpool School of Tropical Medicine (Ref 16-072), which sponsored the study. Written informed consent to participate in the study was obtained by the head of household (or their designate) for all participating households.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are available fomr the Github repository cited withing the article https://github.com/vigg-lstm/llineup-genotyping